Bard Financial Services Inc. Cuts Stock Position in Gilead Sciences, Inc. $GILD

Bard Financial Services Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 27,825 shares of the biopharmaceutical company’s stock after selling 1,020 shares during the quarter. Bard Financial Services Inc.’s holdings in Gilead Sciences were worth $3,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the first quarter valued at about $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital raised its holdings in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on GILD. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $115.39.

Gilead Sciences Stock Down 2.8%

GILD stock opened at $114.55 on Monday. The stock has a 50-day simple moving average of $114.04 and a two-hundred day simple moving average of $110.08. Gilead Sciences, Inc. has a twelve month low of $81.57 and a twelve month high of $121.83. The firm has a market capitalization of $142.13 billion, a PE ratio of 22.82, a PEG ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares of the company’s stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,500 shares of company stock valued at $8,765,395 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.